Brought to you by

Heat Biologics gets IP from Univ. of Miami
27 Feb 2017
Executive Summary
The University of Miami licensed Heat Biologics Inc. a portfolio of patents to use in developing heat shock protein gp96-based vaccines aimed at Zika virus and other infectious diseases including HIV, West Nile, dengue, and yellow fever.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com